1997 Royal College mealist in medicine

August 1997
Clinical & Investigative Medicine;Aug97 Supplement, Vol. 20, pS112
Academic Journal
Presents an abstract of the research manuscript `Experimental investigation of levodopa-induced dyskinesia in a primate model of Parkinsonism,' by P.J. Blanchet.


Related Articles

  • Actions of the D[sub 1] agonists A-77636 and A-86929 on locomotion and dyskinesia in MPTP-treated L-dopa-primed common marmosets. Pearce, R. K. B.; Jackson, M.; Britton, D. R.; Shiosaki, K.; Jenner, P.; Marsden, C. D. // Psychopharmacology;1999, Vol. 142 Issue 1, p51 

    Abstract Common marmosets show parkinsonian motor deficits following 1-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP) administration and develop dyskinesias during chronic L-dopa exposure. The D[sub l] agonists A-77636 [(1R, 3S) 3-(l'-adamantyl)-l-aminomethyl-3, 4-dihydro-5,...

  • Resolution of dyskinesia and the 'on-off' phenomenon in thyrotoxic patients with Parkinson's disease after antithyroid treatment. Caradoc-Davies, T.H. // British Medical Journal (Clinical Research Edition);7/5/1986, Vol. 293 Issue 6538, p38 

    Investigates the dyskinesia and the 'on-off' phenomenon in thyrotoxic patients with Parkinson's disease after antithyroid treatment. Difficulty of diagnosing thyrotoxins; Complications of treatment with compounds containing levodopa; Response of patients to the thyrotrophin releasing hormone...

  • Chronic bilateral pallidal stimulation and levodopa do not improve gait in the same way in Parkinson's disease: a study using a video motion analysis system. Krystkowiak, Pierre; Blatt, Jean Louis; Bourriez, Jean Louis; Duhamel, Alain; Perina, Myriam; Kemoun, Gilles; Blond, Serge; Guieu, Jean Daniel; Dest�e, Alain; Defebvre, Luc // Journal of Neurology;Nov2001, Vol. 248 Issue 11, p944 

    Chronic bilateral internal globus pallidus (GPi) stimulation allows control of levodopa induced dyskinesias (LID) and motor symptoms in severe Parkinson's disease (PD). The effect on gait has not been clearly established. Different results have been reported, mostly consisting of clinical data....

  • Pramipexole + Levodopa in Parkinson's Disease: Is the Whole Greater than the Sum of its Parts? Nirenberg, Melissa J. // Neurology Alert;Mar2010, Vol. 28 Issue 7, p52 

    LEVODOPA AND DOPAMINE AGONISTS (DAS) ARE commonly used treatments for Parkinson's disease (PD). Although DAs tend to have more side effects than levodopa, they are often favored as initial therapy because this strategy delays the onset of motor complications such as wearing off and dyskinesias....

  • Levodopa Response and Prognosis in Parkinson's Disease. Henchcliffe, Claire // Neurology Alert;Sep2007, Vol. 26 Issue 1, p5 

    The authors identified 97 autopsy-proven Parkinson's disease (PD) cases from the Queen's Square Brain Bank between 2001 and 2006, all with long-term levodopa treatment and rigorous clinical documentation. Clinical features were evaluated by chart review. Cerebral pathology was determined by:...

  • Tolcapone increases maximum concentration of levodopa. Müller, T.; Woitalla, D.; Schulz, D.; Peters, S.; Kuhn, W.; Przuntek, H. // Journal of Neural Transmission;Jan2000, Vol. 107 Issue 1, p113 

    Summary. No significant increase of the maximum concentration (Cmax) of levodopa after addition of catechol-O-methyltransferase inhibitor tolcapone occurred in previous pharmacokinetic studies predominantly on healthy volunteers. We compared pharmacokinetics of levodopa in plasma before and...

  • Use of the new levodopa agent Stalevo (levodopa/carbidopa/entacapone) in the treatment of Parkinson's disease in out-patient clinical practice (the START-M open trial). Boiko, A. N.; Batysheva, T. T.; Minaeva, N. G.; Babina, L. A.; Vdovichenko, T. V.; Zhuravleva, E. Yu.; Shikhkerimov, R. K.; Malykhina, E. A.; Khozova, A. A.; Zaitsev, K. A.; Kostenko, E. V. // Neuroscience & Behavioral Physiology;Nov2008, Vol. 38 Issue 9, p933 

    Despite the significant symptomatic effects of levodopa, stable 24-h treatment responses are in the vast majority of patients replaced 2–3 years from the start of treatment by oscillations in motor symptoms (fluctuation, dyskinesia), amelioration of which requires addition of constant...

  • Which factors influence therapeutic decisions in Parkinson's disease? Baas, H.; Fuchs, G.; Gemende, I.; Hueber, R.; Lachenmayer, L.; Schneider, E.; Schoenberger, B.; Werner, M. // Journal of Neurology;Dec2002 Supplement 3, Vol. 249, piii49 

    Development of dyskinesia is a common phenomenon during the long-term course of Parkinson's disease. During the last few years, some but not all pathogenetic mechanisms causing dyskinesias in PD have become better understood. Severity of Parkinson's disease and levodopa dosing are the main...

  • LEVODOPA ASSOCIATED DYSKINESIA IN PARKINSON'S DISEASE IS RELATED TO BODY WEIGHT. Sharma, J.; MacNamara, L.; Vassallo, M. // Age & Ageing;Jul2005 Supplement1, Vol. 34, pi31 

    Discusses research being done on the association between levodopa, dyskinesia and body weight in patients with Parkinson's disease. Reference to a study by J. Sharma and colleagues, presented at the autumn meeting of the British Geriatrics Societies in October 2004; Prevalence of dyskinesia in...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics